EP Patent

EP2835423A1 — Ligase E3 RNF185 inhibitors and uses thereof

Assigned to Commissariat a lEnergie Atomique et aux Energies Alternatives CEA · Expires 2015-02-11 · 11y expired

What this patent protects

The present relates to the use of an E3 ligase RNF185 inhibitor for treating cystic fibrosis and chronic obstructive pulmonary disease.

USPTO Abstract

The present relates to the use of an E3 ligase RNF185 inhibitor for treating cystic fibrosis and chronic obstructive pulmonary disease.

Drugs covered by this patent

Patent Metadata

Patent number
EP2835423A1
Jurisdiction
EP
Classification
—
Expires
2015-02-11
Drug substance claim
No
Drug product claim
No
Assignee
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.